Affinivax is a series c plus startup based in United States. 1 investor tracked. Status: acquired.
Based in the United States, Affinivax is a startup founded in 2014. Affinivax has been acquired. Brouky records 3 investors associated with the company.
Affinivax is a clinical-stage biotechnology company developing a next-generation vaccine platform to design preventive and therapeutic vaccines that aim to provide broader protection against infectious and immune-mediated diseases.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.